SCHEDULE 13G/A: Nantahala Capital Management Discloses 9.99% Stake in Soleno Therapeutics

Nantahala Capital Management, along with its managing members Wilmot B. Harkey and Daniel Mack, has disclosed a beneficial ownership of 9.99% in Soleno Therapeutics, Inc. as of December 31, 2024.

Summary

• Nantahala Capital Management, LLC, an investment adviser, along with its managing members Wilmot B. Harkey and Daniel Mack, collectively reported beneficial ownership of 4,349,435 shares of Soleno Therapeutics, Inc. Common Stock.
• This ownership represents 9.99% of the total outstanding shares of Soleno Therapeutics, Inc.
• The reported shares include 420,469 shares that can be acquired by the reporting persons within sixty days through the exercise of warrants.
• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack each hold shared voting power and shared dispositive power over all 4,349,435 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• BLACKWELL PARTNERS LLC SERIES A, a fund advised by Nantahala, holds the right to receive dividends or proceeds from the sale of more than five percent of the outstanding common stock beneficially owned by Nantahala.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment. It is a neutral, regulatory filing.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment firm, Nantahala Capital Management, maintains a substantial stake in Soleno Therapeutics, a biopharmaceutical company. Such disclosures are common and reflect ongoing portfolio management by investment funds. The 9.99% stake suggests a strong, but passive, interest in the company's future performance.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder (9.99%) may be viewed positively, indicating institutional confidence or interest in Soleno Therapeutics. It also provides transparency regarding major ownership stakes.

Key Dates

Keywords

Soleno Therapeutics, Nantahala Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Institutional Ownership, Warrants, SEC Filing